| Name | Title | Contact Details |
|---|
Hanon Systems is a global provider of automotive thermal and energy management solutions, based in Daejeon, South Korea. Founded in 1986 as Halla Climate Control Corp. through a joint venture between Ford Motor Co. and Mando Machinery Corporation, the company has grown to serve nearly all major automakers. As of 2025, it operates as a subsidiary of Hankook & Company Group, alongside its other core portfolios in tires and batteries. The company specializes in optimizing vehicle performance and occupant comfort through advanced thermal management technologies. Its product offerings include HVAC systems, thermal management components like compressors and cooling modules, and energy efficiency solutions aimed at reducing emissions and improving air quality. Hanon Systems has expanded its capabilities through strategic acquisitions, enhancing its position in the automotive industry. With over 50 facilities worldwide, the company is committed to providing electrification-ready solutions that support the shift toward sustainable mobility.
The Detroit Tigers are a Major League Baseball team based in Detroit, Michigan. One of the American Leagues eight charter franchises, the club was founded in Detroit in 1894. The Tigers have won four World Series championships (1935, 1945, 1968 and 1984) and have won the American League pennant 10 times. Since 2000, the team has played at Comerica Park. Find a listing of available jobs at http://detroit.tigers.mlb.com/careers/opportunities.jsp?c_id=det
Atlas Copco Group enables technology that transforms the future. We innovate to develop products, services and solutions that are key to our customers success. Our four business areas offer compressed air and vacuum solutions, energy solutions, dewatering and industrial pumps, industrial power tools and assembly and machine vision solutions. In 2023, the Group had revenues of BSEK 173, and at year end about 53 000 employees.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.